GSK: positive data for Arexvy RSV vaccine

(CercleFinance.com) - GSK announces that new data from a Phase III trial has demonstrated the efficacy of a single dose of Arexvy vaccine against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 and over, over three full RSV seasons.


Cumulative efficacy was 62.9% against these infections, and 67.4% against severe forms.

The study included adults with underlying pathologies, suggesting a significant impact on public health.

GSK says that it is delighted with this new data, which show that the Arexvy vaccine could help protect millions of older adults.


Copyright (c) 2024 CercleFinance.com. All rights reserved.